Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011 Feb; 25(2):341-7.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.